KORU Medical Systems to Present Data Demonstrating 97% Adherence on Its Freedom Infusion System for Large Volume Subcutaneous Administration at NHIA 2024 Conference

Rhea-AI Summary

KORU Medical Systems, Inc. announces data on the impact of the Freedom Infusion System on subcutaneous immunoglobulin therapy for primary immunodeficiency diseases. The study analyzed data from 3,787 US PIDD patients using KORU Medical infusion systems, showing a 97% adherence rate. The abstract will be presented at the NHIA 2024 Conference by Brent Rutland, VP of Medical Affairs.

MAHWAH, N.J.--(BUSINESS WIRE)-- KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, is pleased to announce data on the impact of the Freedom Infusion System on subcutaneous immunoglobulin (SCIg) therapy for primary immunodeficiency diseases (PIDD) to be presented at the National Home Infusion Association (NHIA) 2024 Conference. The conference will take place from March 23 to 27 in Austin, Texas.

The study, authored by KORU Medical, analyzed data from a large national specialty pharmacy, capturing drug receipts over 4.5 years for 3,787 US PIDD patients using KORU Medical FREEDOM60® and FreedomEdge® infusion systems for self-administered SCIg therapy. Ages ranged from 1 year to 98 years, with a mean of 50.1 years. Patient drug administration volumes ranged from 5mL to greater than 100mL with the majority of patients administering under 50mL. Adherence to SCIg therapy using the KORU Medical FREEDOM60® and FreedomEdge® infusion systems was calculated at 97%.

The abstract, titled "Exploring the Impact of KORU Freedom Infusion Systems on Subcutaneous Immunoglobulin Therapy for Primary Immunodeficiency: Insights from a Large-Scale Database Analysis,” will be presented by Brent Rutland, Vice-President of Medical Affairs for KORU Medical. This study represents the largest cohort of PIDD patients in the literature. We believe it provides valuable insights into the effectiveness of KORU Medical’s Freedom Infusion System in promoting treatment compliance in large volume subcutaneous delivery.

“These findings highlight the positive impact of KORU Medical’s Freedom Infusion System on subcutaneous immunoglobulin therapy for patients with primary immunodeficiency disease," said Brent Rutland, Vice President, Medical Affairs at KORU Medical. "The high adherence rate underscores the effectiveness of KORU Medical’s pumps in promoting treatment compliance and improving patient outcomes. These results, with the KORU Freedom Infusion System, also demonstrate the company’s potential to support a broader range of developmental subcutaneous drug therapies.”

About KORU Medical Systems

KORU Medical develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System (the “Freedom System”) currently includes the FREEDOM60^® and FreedomEdge^® Syringe Infusion Drivers, Precision Flow Rate Tubing^™ and HIgH-Flo Subcutaneous Safety Needle Sets^™. These devices are used for infusions administered in the home and alternate care settings. For more information, please visit www.korumedical.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. All statements that are not historical fact are forward-looking statements and can be identified by words such as “will,” "believe" and "potential". Actual results may differ materially from these statements due to potential risks and uncertainties such as, among others, those risks and uncertainties included under the captions "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, which is on file with the SEC and available on our website at www.korumedical.com/investors and on the SEC website at www.sec.gov. All information provided in this release and in the attachments is as of March 18, 2024. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240318095980/en/

Investor Contact:

Louisa Smith

investor@korumedical.com

Source: KORU Medical Systems, Inc.

FAQ

What is the focus of KORU Medical Systems, Inc. according to the press release?

KORU Medical Systems, Inc. focuses on the development, manufacturing, and commercialization of innovative large volume subcutaneous infusion solutions for patient-centric care.

Where will the data on the impact of the Freedom Infusion System be presented?

The data will be presented at the National Home Infusion Association (NHIA) 2024 Conference in Austin, Texas.

Who will present the abstract at the conference according to the press release?

Brent Rutland, Vice-President of Medical Affairs for KORU Medical, will present the abstract.

What is the adherence rate to SCIg therapy using KORU Medical infusion systems as per the press release?

The adherence rate to SCIg therapy using KORU Medical infusion systems is calculated at 97%.

What does the study represent according to the press release?

The study represents the largest cohort of PIDD patients in the literature, providing valuable insights into the effectiveness of KORU Medical's Freedom Infusion System.